Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G F Fleming

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Gynecologic Oncology|October 20, 2007
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group studyT A Grushko, V L Filiaci, A J Mundt, et al.
Cancer Chemotherapy and Pharmacology|June 15, 2000
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrationsB C Goh, G F Fleming, L Janisch, et al.
Cancer Chemotherapy and Pharmacology|June 10, 1998
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071)S Mani, L Iyer, L Janisch, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitusG F Fleming, E E Vokes, J B Buse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2002
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumorsC Eng, A M Mauer, G F Fleming, et al.
Clinical Pharmacology and Therapeutics|March 1, 1996
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamicsR Mick, E E Vokes, T M Lestingi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2003
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunctionG F Fleming, R L Schilsky, L P Schumm, et al.
Cancer|August 1, 1993
Dedifferentiated chordoma. Response to aggressive chemotherapy in two casesG F Fleming, P S Heimann, J K Stephens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expressionS M Poelman, M O Adeyanju, M A Robertson, et al.
Gynecologic Oncology|April 22, 2015
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II ConsortiaH Hirte, S Lheureux, G F Fleming, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Gynecologic Oncology|October 20, 2007
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group studyT A Grushko, V L Filiaci, A J Mundt, et al.
Cancer Chemotherapy and Pharmacology|June 15, 2000
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrationsB C Goh, G F Fleming, L Janisch, et al.
Cancer Chemotherapy and Pharmacology|June 10, 1998
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071)S Mani, L Iyer, L Janisch, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitusG F Fleming, E E Vokes, J B Buse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2002
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumorsC Eng, A M Mauer, G F Fleming, et al.
Clinical Pharmacology and Therapeutics|March 1, 1996
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamicsR Mick, E E Vokes, T M Lestingi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2003
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunctionG F Fleming, R L Schilsky, L P Schumm, et al.
Cancer|August 1, 1993
Dedifferentiated chordoma. Response to aggressive chemotherapy in two casesG F Fleming, P S Heimann, J K Stephens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expressionS M Poelman, M O Adeyanju, M A Robertson, et al.
Gynecologic Oncology|April 22, 2015
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II ConsortiaH Hirte, S Lheureux, G F Fleming, et al.
Pageof 6